You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Harvard Business School

Last Updated: October 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,459,554

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,459,554 protect, and when does it expire?

Patent 7,459,554 protects CALQUENCE and is included in one NDA.

This patent has twenty patent family members in seventeen countries.

Summary for Patent: 7,459,554
Title:Imidazopyrazine tyrosine kinase inhibitors
Abstract: Compounds of the formula ##STR00001## and pharmaceutically acceptable salts thereof, wherein Q.sup.1 and R.sup.1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.
Inventor(s): Dong; Han-Qing (Syosset, NY), Foreman; Kenneth (Syosset, NY), Mulvihill; Mark Joseph (East Northport, NY), Nigro; Anthony Innocenzo (Westwood, NJ), Steinig; Arno G. (East Northport, NY), Werner; Douglas (Holtsville, NY), Wilkes; Robin (Oxfordshire, GB)
Assignee: OSI Pharmaceuticals, Inc. (Melville, NY)
Application Number:10/965,182
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,459,554
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 7,459,554

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca CALQUENCE acalabrutinib CAPSULE;ORAL 210259-001 Oct 31, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,459,554

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 046337   Start Trial
Austria 525377   Start Trial
Australia 2004282219   Start Trial
Brazil PI0415395   Start Trial
Canada 2542481   Start Trial
China 1898240   Start Trial
European Patent Office 1675860   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.